Early Targeted Antibiotic Therapy in Patients With Sepsis
Primary Purpose
Sepsis
Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
targeted antibiotics therapy
Sponsored by
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
- Male and female patients 18 years or older
- A definite diagnosis of sepsis or septic shock according to the definition of the 2016 SCCM/ESICM task force.
- Patients at risk for carbapenemase producing organisms
Exclusion Criteria:
- Pregnant and lactating women
- hematological disorders (e.g., leukemia, myelodysplastic syndrome, neoplastic metastases to bone marrow),
- life-threatening diseases (e.g., malignant solid tumors), acquired immunodeficiency syndrome.
- Lethal traumatic injury
- Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II) score ≥34 (due to high predicted mortality of 80%)
- Primary fungal or viral infections
Sites / Locations
- Rehab Hussein Werida
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Group A
Group B
Arm Description
antibiotic regimen guided by conventional culture technique (n=24)
targeted antibiotics therapy guided by resistance genotyping (n=24)
Outcomes
Primary Outcome Measures
Sirtuin1 (ng/ml)
Levels of Sirtuin1 will be detected using ELISA kits as prescribed by manufacturer.
SOFA (score)
SOFA score (ΔSOFA) which will be calculated by subtracting the final SOFA score at 5 days from the corresponding initial value at enrollment.
Secondary Outcome Measures
mortality rates (%)
number of dead patients.
ventilator free days (days)
count of days free from ventilator,
length of icu stay (Days)
count of days in ICU
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05459389
Brief Title
Early Targeted Antibiotic Therapy in Patients With Sepsis
Official Title
Efficacy of Early Targeted Antibiotic Therapy in Patients With Sepsis and Septic Shock
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
September 1, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Rehab Werida
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to assess the efficacy of early targeted antibiotic therapy in patients with sepsis and septic shock using the new biomarker Sirtuin 1 and PCR for bacterial resistance detection.
The primary outcome is change in SOFA score (ΔSOFA) which will be calculated by subtracting the final SOFA score and sirtuin 1 level at 5 days from the corresponding initial value at enrollment.
Secondary outcomes included mortality rates, ventilator free days and length of icu stay.
Detailed Description
A prospective, single-center, open labeled, randomized interventional study
Patients will be recruited from a private hospital in Alexandria
Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University
Fourty eight critically ill patients, with sepsis and septic shock according to the 2016 third international consensus definitions, will be included
Patients with risk for Carbapenemase producing organisms:
Use of broad spectrum cephalosporins and/or carbapenems within the past three months
Polytrauma
Diabetes
Malignancy
Organ transplantation
Mechanical ventilation
Indwelling urinary or venous catheters
Overall poor functional status or severe illness
Residence in a long-term care facility(18-28).
The baseline characteristics of the patients will be collected at the time of enrollment. The collected data included age, sex, ratio of septic shock to sepsis, ratio of ventilated to non-ventilated patients, source of infection, vital signs, laboratory data, arterial blood gas (ABG), APACHE II score, Glasgow Coma Scale score, and SOFA scores. The level of Procalcitonin (PCT) and Sirtuin-1 will also be measured at this time(29).
Patients will be randomly allocated to antibiotic regimen guided by conventional culture technique (n=24) or targeted antibiotics therapy guided by resistance genotyping (n=24) (29, 30).
Levels of Sirtuin1 will be detected using ELISA kits as prescribed by manufacturer.
Traditional diagnostic microbiology techniques relying on the growth of organisms on appropriate culture media (Control group).
Qualitative Multiplex pcr test will be used for rapid detection of carbapenemases genes (Intervention group)
Statistical tests appropriate to the study will be conducted to evaluate significance of results
Results, conclusion, discussion and recommendations will be given.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomly allocated to antibiotic regimen guided by conventional culture technique (n=24) or targeted antibiotics therapy guided by resistance genotyping (n=24)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
No Intervention
Arm Description
antibiotic regimen guided by conventional culture technique (n=24)
Arm Title
Group B
Arm Type
Experimental
Arm Description
targeted antibiotics therapy guided by resistance genotyping (n=24)
Intervention Type
Other
Intervention Name(s)
targeted antibiotics therapy
Other Intervention Name(s)
genotyping
Intervention Description
targeted antibiotics therapy guided by resistance genotyping (n=24)
Primary Outcome Measure Information:
Title
Sirtuin1 (ng/ml)
Description
Levels of Sirtuin1 will be detected using ELISA kits as prescribed by manufacturer.
Time Frame
5 days
Title
SOFA (score)
Description
SOFA score (ΔSOFA) which will be calculated by subtracting the final SOFA score at 5 days from the corresponding initial value at enrollment.
Time Frame
5 days
Secondary Outcome Measure Information:
Title
mortality rates (%)
Description
number of dead patients.
Time Frame
5 days
Title
ventilator free days (days)
Description
count of days free from ventilator,
Time Frame
5 days
Title
length of icu stay (Days)
Description
count of days in ICU
Time Frame
5 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients 18 years or older
A definite diagnosis of sepsis or septic shock according to the definition of the 2016 SCCM/ESICM task force.
Patients at risk for carbapenemase producing organisms
Exclusion Criteria:
Pregnant and lactating women
hematological disorders (e.g., leukemia, myelodysplastic syndrome, neoplastic metastases to bone marrow),
life-threatening diseases (e.g., malignant solid tumors), acquired immunodeficiency syndrome.
Lethal traumatic injury
Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II) score ≥34 (due to high predicted mortality of 80%)
Primary fungal or viral infections
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rehab H Werida, Ass. Prof.
Organizational Affiliation
Damanhour University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Noha Elbassiony
Organizational Affiliation
Damanhour University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eman Momtaz
Organizational Affiliation
Damanhour University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rehab Hussein Werida
City
Damanhūr
State/Province
Elbehairah
ZIP/Postal Code
31527
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26903338
Citation
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
Results Reference
background
PubMed Identifier
32274170
Citation
Martinez ML, Plata-Menchaca EP, Ruiz-Rodriguez JC, Ferrer R. An approach to antibiotic treatment in patients with sepsis. J Thorac Dis. 2020 Mar;12(3):1007-1021. doi: 10.21037/jtd.2020.01.47.
Results Reference
result
PubMed Identifier
31768064
Citation
Bhattacharyya RP, Bandyopadhyay N, Ma P, Son SS, Liu J, He LL, Wu L, Khafizov R, Boykin R, Cerqueira GC, Pironti A, Rudy RF, Patel MM, Yang R, Skerry J, Nazarian E, Musser KA, Taylor J, Pierce VM, Earl AM, Cosimi LA, Shoresh N, Beechem J, Livny J, Hung DT. Simultaneous detection of genotype and phenotype enables rapid and accurate antibiotic susceptibility determination. Nat Med. 2019 Dec;25(12):1858-1864. doi: 10.1038/s41591-019-0650-9. Epub 2019 Nov 25.
Results Reference
result
Learn more about this trial
Early Targeted Antibiotic Therapy in Patients With Sepsis
We'll reach out to this number within 24 hrs